Chromosome 13… new marker for B-cell chronic lymphocytic leukemia

B-cell Chronic Lymphocytic Leukemia

Purpose: To review the recent major advances in the molecular and cell biology of B-cell chronic lymphocytic leukemia (B-CLL). Methods: Weanalyzed thenatureofmalignantB-CLLB cells and their interactions with the microenvironment. Results: B-CLL is a malignancy of a mantle zonebased subpopulation of anergic, self-reactive, activated CD51 B cells devoted to the production of polyreactive natural ...

Alemtuzumab for B-cell chronic lymphocytic leukemia.

Alemtuzumab, a humanized monoclonal antibody, is thought to destroy cancer cells through immune system stimulation or apoptosis induction (programmed cell death). In case series studies using alemtuzumab as salvage therapy, about a third of patients with B-cell chronic lymphocytic leukemia (B-CLL), who were otherwise refractory to chemotherapy, improved. Anti-tumour activity was also observed w...

CD69 expression in B-cell chronic lymphocytic leukemia: a new prognostic marker ?

Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia.

Chronic lymphocytic leukemia is an adult-onset leukemia with a heterogeneous clinical behavior. When chronic lymphocytic leukemia cases were divided on the basis of IgV(H) mutational status, widely differing clinical courses were revealed. Since IgV(H) sequencing is difficult to perform in a routine diagnostic laboratory, finding a surrogate for IgV(H) mutational status seems an important prior...

Chronic lymphocytic leukemia, biology, new diagnosis and treatment: review article

Chronic lymphocytic leukemia (CLL) is a malignancy of B CD5+cells and is the most common type of leukemia in adults. The disease is more common in men over 50 years in western countries. CLL is associated with defective apoptosis in B cells. CLL was traditionally regarded as a disease that occurs before naïve B cells meet the antigen in the lymph nodes. Laboratory diagnosis requires white blood...